Reducing the probability of false positive research findings by pre-publication validation – Experience with a large multiple sclerosis database
暂无分享,去创建一个
Katja Ickstadt | Martin Daumer | Ulrike Held | K. Ickstadt | M. Daumer | G. Ebers | U. Held | George Ebers | Moritz Heinz | Siegfried Schach | S. Schach | M. Heinz
[1] G. Ebers,et al. Microsatellites and genome scans — A GAMES postscript , 2007, Journal of Neuroimmunology.
[2] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. , 1999, Brain : a journal of neurology.
[3] P. Donnelly,et al. Replicating genotype–phenotype associations , 2007, Nature.
[4] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.
[5] Axel Wismüller,et al. BMC Neurology BioMed Central , 2006 .
[6] F. Fazekas,et al. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials , 2005, Neurology.
[7] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[8] Philip J. McCarthy,et al. The Use of Balanced Half-Sample Replication in Cross-Validation Studies , 1976 .
[9] D. Lawlor,et al. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? , 2004, The Lancet.
[10] Stephen W Lagakos,et al. Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.
[11] C. Lederer,et al. Disability as an outcome in MS clinical trials , 2008, Neurology.
[12] M. Korenberg,et al. Microarray Data Analysis , 2007, Methods in Molecular Biology.
[13] Yongchao Ge. Resampling-based Multiple Testing for Microarray Data Analysis , 2003 .
[14] J A Frank,et al. MRI T2 lesion burden in multiple sclerosis , 2006, Neurology.
[15] S. le Cessie,et al. Predictive value of statistical models. , 1990, Statistics in medicine.
[16] J. C. van Houwelingen,et al. Predictive value of statistical models , 1990 .
[17] D. Kent,et al. Subgroup analyses in clinical trials. , 2008, The New England journal of medicine.
[18] S. Delgado,et al. Predictors of relapse rate in MS clinical trials , 2008 .
[19] Robert Tibshirani,et al. The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd Edition , 2001, Springer Series in Statistics.
[20] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] L. Kappos,et al. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis , 2006, Neurology.
[22] Subgroup analyses in clinical trials. , 2008, The New England journal of medicine.
[23] D G Altman,et al. What do we mean by validating a prognostic model? , 2000, Statistics in medicine.
[24] John D. Storey,et al. Statistical Significance for Genome-Wide Studies , 2003 .
[25] Alastair Compston,et al. McAlpine's Multiple Sclerosis , 2005 .
[26] D. Allison,et al. Microarray data analysis: from disarray to consolidation and consensus , 2006, Nature Reviews Genetics.
[27] B Bass,et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.
[28] R. Fisher. THE USE OF MULTIPLE MEASUREMENTS IN TAXONOMIC PROBLEMS , 1936 .
[29] J. Brooks. Why most published research findings are false: Ioannidis JP, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece , 2008 .
[30] Trevor Hastie,et al. The Elements of Statistical Learning , 2001 .
[31] Jan P Vandenbroucke,et al. When are observational studies as credible as randomised trials? , 2004, The Lancet.